董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yang Lu | 男 | Chairman of the Board,Chief Executive Officer and Director | 47 | 未披露 | 1699.00 | 2026-04-10 |
| Ping Ji | 女 | Director | 62 | 未披露 | 未持股 | 2026-04-10 |
| Lars Erik Birgerson | 男 | Director | 74 | 未披露 | 未持股 | 2026-04-10 |
| Shaorong Liu | 男 | Independent Director | 48 | 未披露 | 未持股 | 2026-04-10 |
| Ming Lun Alan Tse | 男 | Independent Director | 46 | 未披露 | 未持股 | 2026-04-10 |
| Roger Sawhney | 男 | Independent Director | 56 | 未披露 | 未持股 | 2026-04-10 |
| Baozhong Wei | 男 | Independent Director | 48 | 未披露 | 未持股 | 2026-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yang Lu | 男 | Chairman of the Board,Chief Executive Officer and Director | 47 | 未披露 | 1699.00 | 2026-04-10 |
| Xiaofeng Ye | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2026-04-10 |
| Archie Tse | 男 | President and Head of Research & Development | 59 | 未披露 | 未持股 | 2026-04-10 |
董事简历
中英对照 | 中文 | 英文- Yang Lu
-
杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药行业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012. - 杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药行业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
- Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012.
- Ping Ji
-
Ji Ping，担任Adlai Nortye Ltd.董事，自本次发行完成后生效。她在生物制药药物开发方面拥有超过25年的经验。自2017年7月起，季博士在美国协和麒麟有限公司担任全球安全负责人。在此之前的2011年8月至2017年7月，她在美国拜耳医药保健公司担任全球安全负责人。Ji博士还曾于2006年12月至2011年7月担任美国泰和公司的医疗安全主管，于2004年6月至2006年12月担任美国百时美施贵宝公司的医疗审查员，并于2002年9月至2004年6月担任美国赛诺菲公司的临床科学家。在此之前，从2000年9月至2002年9月，她在辉瑞公司担任临床科学家。1993年5月，Ji博士从罗格斯大学新布朗斯威克研究生院、新泽西州立大学和美国罗伯特·伍德·约翰逊医学院生物医学科学研究生院联合提供的细胞生物学课程中获得了医学硕士学位。1986年8月，她在中国首都医学研究院获得医学博士学位。
Ping Ji has served as Adlai Nortye Ltd.'s director since September 2023. She has over 25 years of experience in biopharmaceutical drug development. Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation. Dr. Ji obtained her Master of Medicine from the cell biology program offered jointly by Graduated School New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986. - Ji Ping，担任Adlai Nortye Ltd.董事，自本次发行完成后生效。她在生物制药药物开发方面拥有超过25年的经验。自2017年7月起，季博士在美国协和麒麟有限公司担任全球安全负责人。在此之前的2011年8月至2017年7月，她在美国拜耳医药保健公司担任全球安全负责人。Ji博士还曾于2006年12月至2011年7月担任美国泰和公司的医疗安全主管，于2004年6月至2006年12月担任美国百时美施贵宝公司的医疗审查员，并于2002年9月至2004年6月担任美国赛诺菲公司的临床科学家。在此之前，从2000年9月至2002年9月，她在辉瑞公司担任临床科学家。1993年5月，Ji博士从罗格斯大学新布朗斯威克研究生院、新泽西州立大学和美国罗伯特·伍德·约翰逊医学院生物医学科学研究生院联合提供的细胞生物学课程中获得了医学硕士学位。1986年8月，她在中国首都医学研究院获得医学博士学位。
- Ping Ji has served as Adlai Nortye Ltd.'s director since September 2023. She has over 25 years of experience in biopharmaceutical drug development. Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation. Dr. Ji obtained her Master of Medicine from the cell biology program offered jointly by Graduated School New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986.
- Lars Erik Birgerson
-
Lars Erik Birgerson将担任Adlai Nortye Ltd.董事，自本次发行完成后生效。自2018年7月起担任Adlai Nortye USA INC总裁兼首席执行官，自2021年7月起担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，伯格森博士担任美国新泽西州伯格森集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医学顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家卫生和福利委员会认证为执业医师。
Lars Erik Birgerson has served as Adlai Nortye Ltd.'s director since September 2023. He served as the president and chief executive officer of Adlai Nortye USA INC from July 2018 to July 2024 and served as Adlai Nortye Ltd.'s chief medical officer from July 2021 to July 2024. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd., Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980. - Lars Erik Birgerson将担任Adlai Nortye Ltd.董事，自本次发行完成后生效。自2018年7月起担任Adlai Nortye USA INC总裁兼首席执行官，自2021年7月起担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，伯格森博士担任美国新泽西州伯格森集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医学顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家卫生和福利委员会认证为执业医师。
- Lars Erik Birgerson has served as Adlai Nortye Ltd.'s director since September 2023. He served as the president and chief executive officer of Adlai Nortye USA INC from July 2018 to July 2024 and served as Adlai Nortye Ltd.'s chief medical officer from July 2021 to July 2024. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd., Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980.
- Shaorong Liu
-
刘绍荣将担任Adlai Nortye Ltd.的独立董事，自本次发行完成后生效。刘先生在企业管理和咨询方面拥有大约15年的经验。自2008年4月起，刘先生一直担任上海智易企业管理咨询有限公司的管理合伙人和高级顾问。此外，刘先生还自2018年4月起担任江苏共创草业股份有限公司（上海证券交易所股票代码：605099）的独立非执行董事。刘先生于2012年9月在中欧国际工商学院获得工商管理硕士学位。
Shaorong Liu has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Liu has approximately 15 years of experience in business management and consulting. Mr. Liu has been serving as the managing partner and senior consultant of Shanghai Zhiyi Enterprise Management Consulting Co., Ltd. since April 2008. Further, Mr. Liu has also been an independent non executive director of Jiangsu CoCreation Grass Co., Ltd. (Shanghai Stock Exchange stock code: 605099) since April 2018. Mr. Liu obtained his master's degree in business administration from the China Europe International Business School in September 2012. - 刘绍荣将担任Adlai Nortye Ltd.的独立董事，自本次发行完成后生效。刘先生在企业管理和咨询方面拥有大约15年的经验。自2008年4月起，刘先生一直担任上海智易企业管理咨询有限公司的管理合伙人和高级顾问。此外，刘先生还自2018年4月起担任江苏共创草业股份有限公司（上海证券交易所股票代码：605099）的独立非执行董事。刘先生于2012年9月在中欧国际工商学院获得工商管理硕士学位。
- Shaorong Liu has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Liu has approximately 15 years of experience in business management and consulting. Mr. Liu has been serving as the managing partner and senior consultant of Shanghai Zhiyi Enterprise Management Consulting Co., Ltd. since April 2008. Further, Mr. Liu has also been an independent non executive director of Jiangsu CoCreation Grass Co., Ltd. (Shanghai Stock Exchange stock code: 605099) since April 2018. Mr. Liu obtained his master's degree in business administration from the China Europe International Business School in September 2012.
- Ming Lun Alan Tse
-
Ming Lun Alan Tse，担任Adlai Nortye Ltd.独立董事，自本次发行完成后生效。谢先生在财务管理和会计方面拥有20多年的经验。谢先生目前担任捷成资本有限公司的总经理和天鸽互动控股有限公司（香港交易所：1980）的独立非执行董事。在此之前，谢先生于2002年9月至2005年5月担任毕马威会计师，于2005年5月至2007年5月担任创科实业有限公司高级分析师。谢先生还曾于2007年9月至2009年8月在Next Horizon有限公司担任企业规划和发展高级经理，并于2009年9月至2011年10月在历峰亚太有限公司担任财务和行政部项目和业务发展经理。自2011年11月起，谢先生担任捷成汽车技术北京有限公司总经理。谢先生于2002年12月在香港大学取得会计和金融工商管理学士学位。自2005年12月以来，他一直是特许公认会计师公会（ACCA）的资深会员。
Ming Lun Alan Tse has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Tse has more than 20 years of experience in financial management and accounting. Mr. Tse currently serves as an independent non executive director of Tian Ge Interactive Holdings Ltd. (HKEx: 1980). Previously, Mr. Tse served as an accountant at KPMG from September 2002 to May 2005, a senior analyst at Techtronic Industries Co., Ltd from May 2005 to May 2007. Mr. Tse also served as a senior manager of corporate planning and development, a senior manager of corporate planning and development at Next Horizon Company Limited from September 2007 to August 2009, and a project and business development manager of finance and administration department at Richemont Asia Pacific Limited from September 2009 to October 2011. Mr. Tse served as a general manager of Jebsen Capital from November 2011 to December 2023. Mr. Tse obtained his Bachelor of Business Administration in accounting and finance from the University of Hong Kong in December 2002. He has been a fellow member of the Association of Chartered Certified Accountants (ACCA) since December 2005. - Ming Lun Alan Tse，担任Adlai Nortye Ltd.独立董事，自本次发行完成后生效。谢先生在财务管理和会计方面拥有20多年的经验。谢先生目前担任捷成资本有限公司的总经理和天鸽互动控股有限公司（香港交易所：1980）的独立非执行董事。在此之前，谢先生于2002年9月至2005年5月担任毕马威会计师，于2005年5月至2007年5月担任创科实业有限公司高级分析师。谢先生还曾于2007年9月至2009年8月在Next Horizon有限公司担任企业规划和发展高级经理，并于2009年9月至2011年10月在历峰亚太有限公司担任财务和行政部项目和业务发展经理。自2011年11月起，谢先生担任捷成汽车技术北京有限公司总经理。谢先生于2002年12月在香港大学取得会计和金融工商管理学士学位。自2005年12月以来，他一直是特许公认会计师公会（ACCA）的资深会员。
- Ming Lun Alan Tse has served as Adlai Nortye Ltd.'s independent director since September 2023. Mr. Tse has more than 20 years of experience in financial management and accounting. Mr. Tse currently serves as an independent non executive director of Tian Ge Interactive Holdings Ltd. (HKEx: 1980). Previously, Mr. Tse served as an accountant at KPMG from September 2002 to May 2005, a senior analyst at Techtronic Industries Co., Ltd from May 2005 to May 2007. Mr. Tse also served as a senior manager of corporate planning and development, a senior manager of corporate planning and development at Next Horizon Company Limited from September 2007 to August 2009, and a project and business development manager of finance and administration department at Richemont Asia Pacific Limited from September 2009 to October 2011. Mr. Tse served as a general manager of Jebsen Capital from November 2011 to December 2023. Mr. Tse obtained his Bachelor of Business Administration in accounting and finance from the University of Hong Kong in December 2002. He has been a fellow member of the Association of Chartered Certified Accountants (ACCA) since December 2005.
- Roger Sawhney
-
Roger Sawhney已被任命为Actuate Therapeutics，Inc.董事，自本次发行完成时生效。Sawhney博士此前于2022年9月至2023年12月期间担任生物技术公司Garuda Therapeutics，Inc.的首席财务官。在此之前，Sawhney博士于2022年5月至2022年9月担任临床阶段生物技术公司Omega Therapeutics, Inc.的首席商务官，并于2020年5月至2022年5月担任其首席财务官。他曾于2018年9月至2020年2月任职于全球投资公司KKR公司，担任其医疗保健投资平台的董事。Sawhney博士还曾于2009年8月至2012年8月担任上市制药公司诺华集团的高级副总裁兼全球企业战略主管，于2017年2月至2018年2月担任医疗保健技术公司Outcome Health的企业战略和业务发展高级副总裁，于2012年8月至2017年2月担任管理咨询公司贝恩公司的合伙人，并于1996年9月至2009年7月担任管理咨询公司波士顿咨询公司的合伙人兼董事总经理。自2024年1月起担任临床阶段免疫肿瘤学公司SIRPant Immunotherapeutics，Inc.的董事，此前于2023年2月至2023年3月担任制药公司Alimera Sciences, Inc.的董事。Sawhney博士获得了哈佛医学院的医学博士学位和斯坦福大学的经济学学士学位。由于Sawhney博士在生物技术和生物制药行业拥有广泛的财务和战略专长，他完全有资格担任董事。
Roger Sawhney,has been appointed to serve as Actuate Therapeutics, Inc. director, effective upon the completion of this offering. Dr. Sawhney previously served as the Chief Financial Officer of Garuda Therapeutics, Inc., a biotechnology company, from September 2022 to December 2023. Prior to this, Dr. Sawhney served as the Chief Business Officer of Omega Therapeutics, Inc., a clinical-stage biotechnology company, from May 2022 to September 2022, and its Chief Financial Officer from May 2020 to May 2022. He served at KKR & Co., a global investment firm, as Director of its healthcare investment platform, from September 2018 to February 2020. Dr. Sawhney also served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, a public pharmaceutical company, from August 2009 to August 2012, Senior Vice President of Corporate Strategy and Business Development for Outcome Health, a healthcare technology company, from February 2017 to February 2018, a Partner with Bain & Company, a management consulting firm, from August 2012 to February 2017, and Partner and Managing Director with the Boston Consulting Group, a management consulting firm, from September 1996 to July 2009. He has served as a director of SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company, since January 2024, and previously served as a director of Alimera Sciences, Inc., a pharmaceutical company, from February 2023 to March 2023. Dr. Sawhney earned an M.D. from Harvard Medical School and a BA in Economics from Stanford University. - Roger Sawhney已被任命为Actuate Therapeutics，Inc.董事，自本次发行完成时生效。Sawhney博士此前于2022年9月至2023年12月期间担任生物技术公司Garuda Therapeutics，Inc.的首席财务官。在此之前，Sawhney博士于2022年5月至2022年9月担任临床阶段生物技术公司Omega Therapeutics, Inc.的首席商务官，并于2020年5月至2022年5月担任其首席财务官。他曾于2018年9月至2020年2月任职于全球投资公司KKR公司，担任其医疗保健投资平台的董事。Sawhney博士还曾于2009年8月至2012年8月担任上市制药公司诺华集团的高级副总裁兼全球企业战略主管，于2017年2月至2018年2月担任医疗保健技术公司Outcome Health的企业战略和业务发展高级副总裁，于2012年8月至2017年2月担任管理咨询公司贝恩公司的合伙人，并于1996年9月至2009年7月担任管理咨询公司波士顿咨询公司的合伙人兼董事总经理。自2024年1月起担任临床阶段免疫肿瘤学公司SIRPant Immunotherapeutics，Inc.的董事，此前于2023年2月至2023年3月担任制药公司Alimera Sciences, Inc.的董事。Sawhney博士获得了哈佛医学院的医学博士学位和斯坦福大学的经济学学士学位。由于Sawhney博士在生物技术和生物制药行业拥有广泛的财务和战略专长，他完全有资格担任董事。
- Roger Sawhney,has been appointed to serve as Actuate Therapeutics, Inc. director, effective upon the completion of this offering. Dr. Sawhney previously served as the Chief Financial Officer of Garuda Therapeutics, Inc., a biotechnology company, from September 2022 to December 2023. Prior to this, Dr. Sawhney served as the Chief Business Officer of Omega Therapeutics, Inc., a clinical-stage biotechnology company, from May 2022 to September 2022, and its Chief Financial Officer from May 2020 to May 2022. He served at KKR & Co., a global investment firm, as Director of its healthcare investment platform, from September 2018 to February 2020. Dr. Sawhney also served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, a public pharmaceutical company, from August 2009 to August 2012, Senior Vice President of Corporate Strategy and Business Development for Outcome Health, a healthcare technology company, from February 2017 to February 2018, a Partner with Bain & Company, a management consulting firm, from August 2012 to February 2017, and Partner and Managing Director with the Boston Consulting Group, a management consulting firm, from September 1996 to July 2009. He has served as a director of SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company, since January 2024, and previously served as a director of Alimera Sciences, Inc., a pharmaceutical company, from February 2023 to March 2023. Dr. Sawhney earned an M.D. from Harvard Medical School and a BA in Economics from Stanford University.
- Baozhong Wei
-
鲍忠伟自2025年7月起担任Adlai Nortye Ltd.独立董事。他在公司治理、财务报告、监管合规方面拥有超过19年的经验。自2017年11月起，魏先生担任BR Business Services Pte Ltd的董事，负责监督业务运营并提供战略指导。魏先生带来了企业融资和咨询服务方面的广泛专业知识。2015年8月至2017年10月，他在BDO Advisory Pte Ltd担任经理助理，专门从事企业融资、估值、财务尽职调查、诉讼支持以及并购活动。在此之前，2014年6月至2015年7月，他在JES International Holdings Limited担任财务经理，负责处理全套公司账户、集团合并、现金流报告，并协助审计程序和税务申报。2012年11月至2014年6月，魏先生在MS Corporate Finance Pte Ltd担任助理经理，专注于公司融资任务，包括公司估值和独立财务顾问服务。魏先生是一名特许会计师（新加坡）和认可税务顾问（公司税和GST）。他也是ACRA注册企业服务提供商和合格的备案代理。魏先生拥有新加坡管理大学金融学硕士学位和牛津布鲁克斯大学会计学学士学位。他在跨境架构、并购和风险管理方面的全面经验，加上与董事会和审计委员会一起工作的亲身经历，提供了宝贵的财务专业知识和战略洞察力，与公司的公司治理要求非常吻合。
Baozhong Wei has served as Adlai Nortye Ltd.'s independent director since July 2025. He has more than 19 years of experience in corporate governance, financial reporting, and regulatory compliance. Since November 2017, Mr. Wei has served as a director of BR Business Services Pte Ltd, where he oversees business operations and provides strategic guidance. Prior to that, from June 2014 to July 2015, he was a finance manager at JES International Holdings Limited, where he handled full sets of company accounts, group consolidation, cash flow reporting, and assisted with audit procedures and tax filings. From November 2012 to June 2014, Mr. Wei worked as an assistant manager at MS Corporate Finance Pte Ltd, focusing on corporate finance assignments including company valuations and independent financial adviser services. Mr. Wei is a Chartered Accountant (Singapore) and an Accredited Tax Advisor (Corporate Tax and GST). He is also an ACRA registered Corporate Services Provider and qualified Filing Agent. Mr. Wei holds a Master's degree in Finance from Singapore Management University and a Bachelor's degree in Accountancy from Oxford Brookes University. - 鲍忠伟自2025年7月起担任Adlai Nortye Ltd.独立董事。他在公司治理、财务报告、监管合规方面拥有超过19年的经验。自2017年11月起，魏先生担任BR Business Services Pte Ltd的董事，负责监督业务运营并提供战略指导。魏先生带来了企业融资和咨询服务方面的广泛专业知识。2015年8月至2017年10月，他在BDO Advisory Pte Ltd担任经理助理，专门从事企业融资、估值、财务尽职调查、诉讼支持以及并购活动。在此之前，2014年6月至2015年7月，他在JES International Holdings Limited担任财务经理，负责处理全套公司账户、集团合并、现金流报告，并协助审计程序和税务申报。2012年11月至2014年6月，魏先生在MS Corporate Finance Pte Ltd担任助理经理，专注于公司融资任务，包括公司估值和独立财务顾问服务。魏先生是一名特许会计师（新加坡）和认可税务顾问（公司税和GST）。他也是ACRA注册企业服务提供商和合格的备案代理。魏先生拥有新加坡管理大学金融学硕士学位和牛津布鲁克斯大学会计学学士学位。他在跨境架构、并购和风险管理方面的全面经验，加上与董事会和审计委员会一起工作的亲身经历，提供了宝贵的财务专业知识和战略洞察力，与公司的公司治理要求非常吻合。
- Baozhong Wei has served as Adlai Nortye Ltd.'s independent director since July 2025. He has more than 19 years of experience in corporate governance, financial reporting, and regulatory compliance. Since November 2017, Mr. Wei has served as a director of BR Business Services Pte Ltd, where he oversees business operations and provides strategic guidance. Prior to that, from June 2014 to July 2015, he was a finance manager at JES International Holdings Limited, where he handled full sets of company accounts, group consolidation, cash flow reporting, and assisted with audit procedures and tax filings. From November 2012 to June 2014, Mr. Wei worked as an assistant manager at MS Corporate Finance Pte Ltd, focusing on corporate finance assignments including company valuations and independent financial adviser services. Mr. Wei is a Chartered Accountant (Singapore) and an Accredited Tax Advisor (Corporate Tax and GST). He is also an ACRA registered Corporate Services Provider and qualified Filing Agent. Mr. Wei holds a Master's degree in Finance from Singapore Management University and a Bachelor's degree in Accountancy from Oxford Brookes University.
高管简历
中英对照 | 中文 | 英文- Yang Lu
杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药行业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012.- 杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药行业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
- Yang Lu serves as Adlai Nortye Ltd.'s chief executive officer and the chairman of Adlai Nortye Ltd.'s board of directors. Mr. Lu has over 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd.'s company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA Executive Master of Business Administration from China Europe International Business School in September 2012.
- Xiaofeng Ye
叶晓峰自2026年4月起担任Adlai Nortye Ltd.的首席财务官，于2025年1月至2026年4月担任Adlai Nortye Ltd.的临时首席财务官，并于2017年4月至2026年4月担任Adlai Nortye Ltd.的业务发展和商业化战略副总裁，在生物制药行业内带来了超过17年的业务发展、销售、营销和商业化方面的专业知识。在担任之前的职务时，叶博士是全球领先的生物制药解决方案提供商inVentiv Health（现为Syneos Health）的业务发展副总裁。在他任职期间，他在品牌医药产品在美国和欧洲市场的成功商业发布中发挥了关键作用。此外，叶博士通过管理商业业务部门和在中国为跨国制药公司建立医学教育团队，在亚太地区展示了领导力。在加入inVentiv Health之前，Dr. Ye曾在新泽西州金斯瑞担任区域销售经理，随后在Patheon（现隶属于赛默飞世尔）担任业务发展总监，Patheon是生物制剂CDMO服务的全球领导者。叶博士拥有厦门大学理学学士和理学硕士学位，并在得克萨斯大学MD安德森癌症中心获得博士学位。
Xiaofeng Ye has served as Adlai Nortye Ltd.'s chief financial officer since April 2026, Adlai Nortye Ltd.'s interim chief financial officer from January 2025 to April 2026 and Adlai Nortye Ltd.'s vice president of business development & commercialization strategy from April 2017 to April 2026, has over 17 years of expertise in business development, sales, marketing, and commercialization within the biopharmaceutical industry. In his previous role, Dr. Ye was the Vice President of Business Development at inVentiv Health (now Syneos Health), a leading global biopharma solutions provider. During his tenure, he played a key role in the successful commercial launches of branded pharmaceutical products across the U.S. and European markets. Additionally, Dr. Ye demonstrated leadership in the Asia Pacific region by managing commercial business units and establishing medical education teams for multinational pharmaceutical companies in China. Before his work at inVentiv Health, Dr. Ye served as Regional Sales Manager at GenScript in New Jersey, followed by his role as Business Development Director at Patheon (now part of Thermo Fisher Scientific), a global leader in biologics CDMO services. Dr. Ye holds a Bachelor of Science and a Master of Science from Xiamen University and earned his Ph.D. at the University of Texas MD Anderson Cancer Center.- 叶晓峰自2026年4月起担任Adlai Nortye Ltd.的首席财务官，于2025年1月至2026年4月担任Adlai Nortye Ltd.的临时首席财务官，并于2017年4月至2026年4月担任Adlai Nortye Ltd.的业务发展和商业化战略副总裁，在生物制药行业内带来了超过17年的业务发展、销售、营销和商业化方面的专业知识。在担任之前的职务时，叶博士是全球领先的生物制药解决方案提供商inVentiv Health（现为Syneos Health）的业务发展副总裁。在他任职期间，他在品牌医药产品在美国和欧洲市场的成功商业发布中发挥了关键作用。此外，叶博士通过管理商业业务部门和在中国为跨国制药公司建立医学教育团队，在亚太地区展示了领导力。在加入inVentiv Health之前，Dr. Ye曾在新泽西州金斯瑞担任区域销售经理，随后在Patheon（现隶属于赛默飞世尔）担任业务发展总监，Patheon是生物制剂CDMO服务的全球领导者。叶博士拥有厦门大学理学学士和理学硕士学位，并在得克萨斯大学MD安德森癌症中心获得博士学位。
- Xiaofeng Ye has served as Adlai Nortye Ltd.'s chief financial officer since April 2026, Adlai Nortye Ltd.'s interim chief financial officer from January 2025 to April 2026 and Adlai Nortye Ltd.'s vice president of business development & commercialization strategy from April 2017 to April 2026, has over 17 years of expertise in business development, sales, marketing, and commercialization within the biopharmaceutical industry. In his previous role, Dr. Ye was the Vice President of Business Development at inVentiv Health (now Syneos Health), a leading global biopharma solutions provider. During his tenure, he played a key role in the successful commercial launches of branded pharmaceutical products across the U.S. and European markets. Additionally, Dr. Ye demonstrated leadership in the Asia Pacific region by managing commercial business units and establishing medical education teams for multinational pharmaceutical companies in China. Before his work at inVentiv Health, Dr. Ye served as Regional Sales Manager at GenScript in New Jersey, followed by his role as Business Development Director at Patheon (now part of Thermo Fisher Scientific), a global leader in biologics CDMO services. Dr. Ye holds a Bachelor of Science and a Master of Science from Xiamen University and earned his Ph.D. at the University of Texas MD Anderson Cancer Center.
- Archie Tse
Archie Tse自2026年4月起担任Adlai Nortye Ltd.总裁，自2024年3月起担任Adlai Nortye Ltd.研发主管。在加入Adlai Nortye Ltd.之前，Archie Tse博士曾担任基石药业首席科学官、高级副总裁、研究和早期临床开发负责人以及CMC部门负责人。在此之前，谢博士曾在包括MSD和第一三共在内的跨国公司担任领导职务。Tse博士在南加州大学获得医学博士学位和生物化学与分子生物学博士学位。
Archie Tse has served as Adlai Nortye Ltd.'s president since April 2026 and Adlai Nortye Ltd.'s head of research and development since March 2024. Prior to joining Adlai Nortye Ltd., Dr. Archie Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC Department of CStone Pharmaceuticals. Before that, Dr. Tse held leadership positions in multinational companies, including MSD and Daiichi Sankyo. Dr. Tse obtained his Doctor of Medicine degree and his Doctor of Biochemistry and Molecular Biology degree from University of Southern California.- Archie Tse自2026年4月起担任Adlai Nortye Ltd.总裁，自2024年3月起担任Adlai Nortye Ltd.研发主管。在加入Adlai Nortye Ltd.之前，Archie Tse博士曾担任基石药业首席科学官、高级副总裁、研究和早期临床开发负责人以及CMC部门负责人。在此之前，谢博士曾在包括MSD和第一三共在内的跨国公司担任领导职务。Tse博士在南加州大学获得医学博士学位和生物化学与分子生物学博士学位。
- Archie Tse has served as Adlai Nortye Ltd.'s president since April 2026 and Adlai Nortye Ltd.'s head of research and development since March 2024. Prior to joining Adlai Nortye Ltd., Dr. Archie Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC Department of CStone Pharmaceuticals. Before that, Dr. Tse held leadership positions in multinational companies, including MSD and Daiichi Sankyo. Dr. Tse obtained his Doctor of Medicine degree and his Doctor of Biochemistry and Molecular Biology degree from University of Southern California.